Innovative GFAP blood biomarker test expands Labcorp's (LH) portfolio of tests for diseases including Alzheimer's disease, multiple sclerosis, glioblastoma and brain injuries BURLINGTON, N.C., April ...
BURLINGTON, N.C., Feb. 11, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the nationwide availability of the Elecsys® ...
Labcorp is a science and healthcare company that provides laboratory testing services worldwide. It also functions as a lab facility that conducts research, clinical studies, diagnostic testing, and ...
Addition of pTau217 test further expands the company's leadership in testing options for Alzheimer's disease to improve patient care Alzheimer's disease, the most prevalent form of dementia, poses a ...
Laboratory Corporation of America Holdings LH, known as LabCorp, recently launched the Labcorp Clinical Decision Support (CDS) interpretative test report for its Stinging Insect Component-Specific IgE ...
Labcorp Holdings, Inc. LH has announced the nationwide availability of the Lumipulse pTau-217/Beta Amyloid 42 Ratio — the first FDA-cleared blood-based in-vitro diagnostic (IVD) test to assist in ...
Laboratory Corporation of America Holdings or LabCorp LH recently gained FDA emergency use authorization (EUA) for its VirSeq SARS-CoV-2 NGS (next-generation sequencing) Test on the PacBio Sequel II ...
Elecsys® pTau-181 test helps clinicians rule out Alzheimer's disease by identifying patients unlikely to have amyloid pathology Now available nationwide in primary care settings for patients aged 55 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results